Using Polymers To Improve Drug Formulations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Using Polymers To Improve Drug Formulations


Pharmaceutical Technology Europe


Tim Bee. Senior Director, Pharmaceuticals, at ISP Pharmaceuticals.
Polymeric excipients have been used in the pharma industry for years. Historically, their greatest use has been as binders and disintegrants to improve the physical properties of granules and tablets. More recently, polymers have been used to control and modify drug release. This trend started with sustained release technologies, with the gelling properties of polymers being used to slow drug release by diffusion through a hydrogel matrix. Enteric polymers target the release of a drug at different points in the gastrointestinal tract using polymers that are soluble at different pH ranges.

The use of polymers to control and modify drug release is expected to continue to grow as formulators understand how to better use the functional properties and benefits of polymers to enhance the performance of their drug products. This increased use of the functional benefits of polymers will allow more NCEs to be brought to market and support the development of more line‑extension products of existing APIs.

Solid dispersion technology

Most recently, polymers are being used to form solid dispersions of poorly soluble drugs to enhance their solubility and bioavailability. Polymers play two roles in solid dispersion technology used to improve drug solubility. The first role is to enhance the physical stability of the amorphous drug and prevent drug recrystallisation during production and storage. The second is to prevent the drug from recrystallising in vivo.

During production and storage, the polymer can prevent the drug from crystallising through both thermodynamic and kinetic mechanisms. In the case of thermodynamic stabilisation, there is sufficient enthalpic interaction between the polymer and the drug for the drug to molecularly dissolve in the polymer — much like sugar dissolves in water. In the case of kinetic stabilisation, the high‑glass transition temperature of the polymer helps to increase the glass transition temperature of the polymer‑drug matrix, which reduces the molecular mobility of the drug, inhibiting crystal nucleation and crystal growth in particular. Thermodynamic stabilisation is the preferred mechanism because there is no threat of recrystallisation on any time‑scale, although kinetic stabilisation can be effective as well.

Solid dispersion technology works particularly well with APIs that have limited solubility because of high crystal lattice energies and high melting points. Formation of the amorphous form of the drug in a solid dispersion eliminates the energy barrier required to break down the crystal lattice structure of the drug, which is the first step in its dissolution.

Future improvements

There is still a lot to learn about solid dispersion technology; however, it provides another option in a formulator’s toolbox to address the challenges presented by poorly soluble drugs. With self‑emulsifying systems, micronisation, nanocrystals, cyclodextrins, surfactants, liquid‑filled soft gels and solid dispersions, formulators have multiple technologies at their disposal to formulate poorly soluble drugs. None of these technologies is a panacea and each has its advantages and limitations, but having multiple options means formulators are more likely to find a technology that works well for their specific API.

In the future, the biggest improvements relating to polymeric excipients will come from a better understanding of how existing polymers perform in existing systems, as well as the advantages and limitations of the different polymers in combination with different types of APIs in different formulations. Once this information is known, formulators will be able to combine different polymers in new ways that bring synergistic benefits to their formulations.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology Europe,
Click here